- RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection;
- RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and
- RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes.
The company has strategic alliances with:
- GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases;
- Sanofi to discover and develop microRNA therapeutics for fibrotic diseases;
- AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and
- Biogen Inc. to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.
Hey Morefun, its entertaining following you. I have no horse in this race. But wondering, is there a point when you would buy UVXY? Let's say after Brexit settles down and everyone focuses on fundamentals. Just curious if you see this a long play at some point.
Based on on its avg pps over the last 6 months, I figure the offering would be between $16-17. It is hard to believe that the offering price would be closer to 6 month low than the 6 month high, especially after the recent positive results.
PRTK only averages 77,000 shares/day with a low 11M float. It should be interesting tomorrow morning. These results could put valuation through the roof. Bid/ask tomorrow should be wild.
Finally a positive sign....
"The man in charge of Mirati Therapeutics Inc. (NASDAQ:MRTX) also bought a sizable block of shares earlier this week. President and CEO Charles M. Baum purchased 20,000 shares on Tuesday at prices that ranged from $6.96 to $7.14 per share, boosting his ownership to 48,556 shares."
I am in at these depths.... consensus price target of $41.40 and a 52-week range of $26.50 to $106.49.
I agree this is over done and should bounce big. But it looks like it needed to test the Aug 2013 lows, which it is doing now. I am in at these levels. Unless markets crash next week, this should bounce nicely. It may bounce regardless of the markets.
It is down 20% now. But analysts were not expecting much from RH which is why it drifted from the mid 40's in April down mid 30's in June. Talking heads on CNBC are implying that RH's current multiple is ridiculously low and RH is at a worthwhile entry point.
That is the silver lining. The 70M trade secret claim for relief does hurt though
Jeffrey analyst Cohen added ... “As a result of the announcement, and until we are able to garner more pertinent information from various parties regarding the company's path ahead, we are reducing our rating from Buy to Neutral with no current associated price target,” Cohen commented.
They will explore options regarding post-trial motions in the trial court and, potentially, the appellate process.
B_roberts, I will give you your dues. Good call. I am out of TRKK, but have an eye on it.
The dilutions has obviously played a part here. But the earnings news was very encouraging. The question is, what is the balance point between the impact of dilution and the prospects of future revenue growth?
You can short stocks under $5 and YES you can short OTC and Pink Sheet stocks. Not all brokers allow it though.
So get your facts right before name calling. OR are you just a short. Come on,... screaming dilution and other P&D. Douth protest too much. Hmmm....
I agree. Its shorts who are yelling pump and dump. Why would anyone care otherwise. Shorts are definitely at risk tomorrow morning.
I agree with retracing, but the other way. It will retrace it way back to .90+, were it was in January. TRKK will be back up to its previous reading range before the last 4 month fall. Then we can see where it goes from there.
David Phipps, Chief Executive Officer of Orbital Tracking Corp. "As now being demonstrated in our financial results, our continued growth in product sales is producing a meaning shift in our business, one towards higher-margin, recurring revenue based on airtime usage from our growing customer base. Looking ahead to the remainder of 2016, we have reason to be optimistic that demand for our products remain strong and that top line revenue will to grow while margins continue to improve."
TRKK has passed a couple of more potential resistance points. Very impressive!
Some posters (panic shorts I am guessing) are trying to say this is a pump and dump. TRKK came out with very strong earnings for a small float stock. People are just now figuring out how strong TRKK will be and are jumping on it.
That is not a pump and dump. If you want to look at a real pump and dump, look at APHD. APHD was .01 on Friday. They announced a new contract, but did not provide any details. That went from .01 to over .20 without any details. Now APHD is .12 and fading. APHD was a true pump and dump. TRKK should not be confused with that.
Not only is TRKK way above daily volume, but the bid/ask volume size is crazy high!!
Interest right now is intense! .20 looks like the launching point.!
TRKK just moved past the 1st resistance point on a volume spike. Volume is sustaining. .95 stock in January. The fall from .95 over the last months has few resistance/support levels. So it will be interesting to see how high this trades over the next 1-2 weeks.